Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Study of the Clearance of Minimal Residual Disease Measured at the End of First-line Treatment in Patients Treated for B-cell Lymphoma or Hodgkin Lymphoma

NCT06744075 is registered in ClinicalTrials.gov with Centre Henri Becquerel as lead sponsor.

NCT NCT06744075
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06744075 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Study of the Clearance of Minimal Residual Disease Measured at the End of First-line Treatment in Patients Treated for B-cell Lymphoma or Hodgkin Lymphoma
Lead sponsor
Centre Henri Becquerel
Phase
Not applicable
Overall status
Active, not recruiting
Start date
December 24, 2024
Completion date
December 20, 2027
Enrollment
108 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

b-cell lymphoma, hodgkin lymphoma